Can GLP-1 Medicines Reduce Diabetes Complications? Evidence Depends on the Drug

"GLP-1 medicines reduce diabetes complications" is too broad to be accurate on its own. Different products have different trial programs, approved uses and study populations. Some have shown reductions in specific heart or kidney outcomes in people with type 2 diabetes who were already at high risk. Those findings are best described medicine by medicine and outcome by outcome.

What the evidence looks like (US labels, as of October 2026)

• Ozempic (semaglutide injection) is approved to improve blood sugar, to lower the risk of major cardiovascular events (heart attack, stroke or cardiovascular death) in adults with type 2 diabetes and established heart disease, and to lower kidney and cardiovascular risks in adults with type 2 diabetes and chronic kidney disease. That kidney indication comes from the FLOW trial: 3,533 people with type 2 diabetes and chronic kidney disease, followed for a median of 3.4 years. Semaglutide 1 mg weekly lowered the risk of the main kidney-and-heart composite outcome by 24% compared with placebo (hazard ratio 0.76).
• Mounjaro (tirzepatide) gained a US indication in August 2026 to reduce major cardiovascular events in adults with type 2 diabetes at high cardiovascular risk. That's based on SURPASS-CVOT, which compared it with another GLP-1 medicine, dulaglutide, and found it non-inferior (not worse), rather than comparing it with placebo.
• Wegovy's cardiovascular indication comes from the SELECT trial, which deliberately excluded people with diabetes. It's important evidence, but it doesn't describe diabetes complications.

Trial populations, comparison treatments and combined endpoints all differ, so these findings can't be merged into one blanket claim for the whole class.

Not every complication moves the same way

Eyes are a good example. In a 2-year trial of people with type 2 diabetes and high cardiovascular risk, diabetic retinopathy complications were more common with Ozempic (3.0%) than placebo (1.8%), mostly in people who already had retinopathy (8.2% vs 5.2%). Rapid improvements in blood sugar can temporarily worsen retinopathy, and the long-term effect hasn't been studied. That's why the label advises monitoring people with a history of retinopathy, and why regular eye exams still matter.

Why this matters for individual care

A person may be prescribed a GLP-1 medicine for blood-sugar control, weight management or another specific use. The care team weighs kidney function, heart history, other medicines, side effects, cost and access, and local labeling. A result from a high-risk trial population may not apply directly to someone with a different history.

Keep the rest of diabetes care going

Even when a medicine lowers an important risk, it doesn't replace glucose monitoring, blood-pressure and cholesterol care, kidney tests, or regular eye and foot checks. Don't reduce or stop another prescription because a new drug got a good headline; any changes belong with your prescriber. If you take insulin or a sulfonylurea, ask how low blood sugar risk will be managed when a GLP-1 is added.

Questions to ask

Which complication does this medicine have evidence or an approved indication to reduce? Do I resemble the people in that trial? How will my kidneys, eyes and heart be monitored? If you see more than one specialist, ask how they'll coordinate. For a side-by-side of the two best-known options, see Mounjaro vs Ozempic.

The encouraging story is that diabetes research increasingly measures outcomes beyond blood sugar. The accurate story stays specific: check the exact product, population, endpoint and local label before drawing conclusions.